Associations of P16INK4a promoter hypermethylation with squamous intra-epithelial lesion, cervical cancer and their clinicopathological features: a meta-analysis.
To assess the associations of P16INK4a methylation status with low-grade squamous intra-epithelial lesion (LSIL), high-grade squamous intra-epithelial lesion (HSIL), cervical cancer (CC) and their clinicopathological features, a meta-analysis with 29 eligible studies was conducted. Pooled odds ratios (ORs) with their 95% confidence intervals (CIs) were estimated to assess the strength of the associations. Heterogeneity, sensitivity of pooled results and publication bias were also evaluated. Overall, there was an increasing trend of P16INK4a hypermethylation rates among LSIL (21.4%), HSIL (30.9%) and CC (35.0%) specimens. P16INK4a hypermethylation was significantly associated with the increased risk of LSIL, HSIL and CC, with the pooled ORs of 3.26 (95% CI: 1.86-5.71), 5.80 (95% CI: 3.80-8.84) and 12.17 (95% CI: 5.86-25.27), respectively. A significant association was also found between P16INK4a hypermethylation and smoking habit (OR = 3.88, 95% CI: 2.13-7.08). Taken together, meta-analysis results support P16INK4a hypermethylation as an epigenetic marker for the progression of cervical carcinogenesis.
Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Ya-di
YD
Han
Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Xue-Bin
XB
Wang
Department of Clinical Laboratory, Children's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Ning-Hua
NH
Cui
Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Shuai
S
Zhang
Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Chen
C
Wang
Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Fang
F
Zheng
D002584:Cervix Uteri / Q000473:pathology; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics*; D019175:DNA Methylation / Q000235:genetics*; D005260:Female; D006801:Humans; D016017:Odds Ratio; D011401:Promoter Regions, Genetic / Q000235:genetics*; D012907:Smoking; D065310:Squamous Intraepithelial Lesions of the Cervix / Q000235:genetics* / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000473:pathology; D002578:Uterine Cervical Dysplasia / Q000235:genetics* / Q000473:pathology
D019941:Cyclin-Dependent Kinase Inhibitor p16
P16INK4a promoter hypermethylation; cervical cancer; meta-analysis; smoking habit; squamous intra-epithelial lesion
J Hepatol. 2010 Sep;53(3):508-18
20561699
J Clin Invest. 2010 Feb;120(2):521-32
20093774
Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1126-34
22564870
Int J Cancer. 2006 Sep 1;119(5):1023-7
16570269
Cancer Cytopathol. 2011 Apr 25;119(2):92-101
21433001
Exp Mol Pathol. 2015 Apr;98(2):308-11
25579180
BMJ. 2008 Apr 26;336(7650):924-6
18436948
Dis Markers. 2014;2014:260549
24803719
Int J Gynecol Cancer. 2006 May-Jun;16(3):1234-40
16803511
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12754-9
10535995
PLoS Med. 2012;9(5):e1001216
22675273
BMC Cancer. 2007 Mar 14;7:47
17359536
Eur J Cancer. 2008 Nov;44(16):2496-505
18722107
Int J Oncol. 2011 Sep;39(3):683-8
21674126
Int J Gynecol Cancer. 2011 Apr;21(3):452-6
21436693
BMJ. 2009 Jul 21;339:b2535
19622551
Cancer Cytopathol. 2016 Jan;124(1):58-65
26335500
Biochim Biophys Acta. 2016 Apr;1865(2):275-88
27085853
Gynecol Oncol. 2010 Jan;116(1):99-104
19836067
Curr Opin Clin Nutr Metab Care. 2007 Sep;10(5):576-81
17693740
Exp Mol Pathol. 2015 Aug;99(1):95-9
26057833
Gynecol Oncol. 2004 May;93(2):435-40
15099958
Cancer Discov. 2016 Apr;6(4):353-67
26658964
PLoS One. 2013 Apr 15;8(4):e60996
23596512
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):553-60
23549399
BMJ. 2003 Sep 6;327(7414):557-60
12958120
Int J Clin Oncol. 2014 Feb;19(1):127-32
23494221
Pathol Int. 2015 Sep;65(9):476-85
26222671
Int J Cancer. 2009 Dec 15;125(12):2995-3002
19609949
Cancer Med. 2015 Mar;4(3):342-53
25619363
Br J Cancer. 2013 Jun 25;108(12):2542-8
23703248
Am J Obstet Gynecol. 2004 Mar;190(3):674-9
15041998
Diagn Mol Pathol. 2010 Mar;19(1):15-9
20186007
Rev Inst Med Trop Sao Paulo. 2013 Sep-Oct;55(5):329-34
24037287
Sci Rep. 2015 Sep 04;5:13563
26338139
JAMA. 2002 Apr 24;287(16):2114-9
11966386
Clin Cancer Res. 2001 Jul;7(7):1982-6
11448914
CA Cancer J Clin. 2015 Mar;65(2):87-108
25651787
Gynecol Oncol. 2003 Dec;91(3):476-85
14675665
Clin Cancer Res. 2001 Mar;7(3):584-9
11297252
Br J Cancer. 2011 Apr 26;104(9):1500-4
21487403
Int J Cancer. 2006 Mar 15;118(6):1481-95
16206285
Am J Epidemiol. 2005 Aug 1;162(3):201-11
15987731
J Natl Cancer Inst. 2000 May 3;92(9):690-8
10793105
Contemp Clin Trials. 2007 Feb;28(2):105-14
16807131
J Cancer Res Clin Oncol. 2005 Jun;131(6):364-70
15785933
Int J Cancer. 2010 Dec 15;127(12):2893-917
21351269
J Natl Cancer Inst. 2005 Feb 16;97(4):273-82
15713962
Cancer. 2004 Aug 25;102(4):259-68
15368319
Br J Cancer. 1999 May;80(3-4):458-67
10408854
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Diagn Mol Pathol. 2006 Jun;15(2):74-82
16778587
Oncol Res. 2009;18(4):185-92
20112504
Infect Dis Obstet Gynecol. 2011;2011:927861
21747645
Int J Cancer. 2012 Nov 15;131(10):2349-59
22323075
BMC Cancer. 2006 Aug 23;6:212
16928264
Oncol Lett. 2012 Jun;3(6):1331-1335
22783444
Mol Biol (Mosk). 2006 Mar-Apr;40(2):224-30
16637262
Oncogene. 2007 Aug 30;26(40):5900-10
17369845
Sci Rep. 2015 Mar 10;5:8897
25754026
J Korean Med Sci. 2005 Aug;20(4):636-42
16100457
Cancer Lett. 1999 Mar 1;136(2):231-5
10355753
Clin Cancer Res. 2011 Apr 15;17(8):2459-65
21389098